Last year, Uganda introduced the injectable ARV Cabotegravir as a pre-exposure prophylaxis (PrEP) option for HIV prevention and treatment, but its usage remains limited due to availability challenges.
In a large scale study code-named HPTN 083 that has been halted because of the Coronavirus pandemic, a bi-monthly injection was found to be safe and effective in preventing infection among cisgender men and transgender women who have sex with men.
